Merck, also known as MSD, is a company that focuses on developing innovative medicines and vaccines to help improve and save lives. They recently announced their financial results for the fourth quarter and full year of 2024. The company's worldwide sales grew by 7%, reaching $15.6 billion in the fourth quarter and $64.2 billion for the full year. KEYTRUDA, a key product of Merck, saw a sales growth of 18% to $29.5 billion. Despite some declines in sales for other products, overall, the company showed a positive financial performance. In the fourth quarter, Merck achieved significant milestones in its pipeline by announcing positive trial results for cancer treatments and receiving FDA acceptance for a new antibody for RSV disease. The company also expanded its pipeline through exclusive global licenses for new investigational drugs. Looking ahead to 2025, Merck anticipates sales between $64.1 billion and $65.6 billion. They also expect non-GAAP EPS to be between $8.88 and $9.03 for the year. The company continues to focus on advancing their pipeline and delivering innovative health solutions. In conclusion, Merck is a leading biopharmaceutical company that is dedicated to improving global health through its innovative medicines and vaccines. With a strong financial performance and a promising pipeline of new treatments, Merck is poised for continued growth and success in the future.